^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    polzastobart (JTX-8064)

    i
    Associations
    News

    Trials

    Company:
    Concentra Biosci
    Drug class:
    HLA G inhibitor, ILT-4 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (INNATE) (NCT04669899)
    Phase 1/2
    Jounce Therapeutics, Inc.
    Completed
    Last update posted :
    04/09/2024
    Initiation :
    01/12/2021
    Primary completion :
    11/28/2023
    Completion :
    11/28/2023
    EGFR • PD-L1 • ALK • IDH1 • FGFR
    |
    EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation
    |
    pimivalimab (JTX-4014) • polzastobart (JTX-8064)